Oral semaglutide further reduced LDL cholesterol on top of maximal lipid-lowering therapy in familial hypercholesterolemia | Research

The takeaway

In a patient with familial hypercholesterolemia already on statins, ezetimibe, and evolocumab (LDL ~50 mg/dL), adding oral semaglutide for diabetes further reduced LDL cholesterol beyond this intensive lipid-lowering regimen.

LDL reduced beyond maximal therapy
Oral semaglutide lowered LDL further on top of statin + ezetimibe + evolocumab in familial hypercholesterolemia—an additive effect no other GLP-1 drug has demonstrated

What the researchers found

Baseline LDL: 312 mg/dL → ~50 mg/dL on statin + ezetimibe + evolocumab. Addition of oral semaglutide: further LDL reduction. Dual benefit: diabetes control + additional LDL lowering beyond maximal therapy.

Why it matters

Residual cardiovascular risk persists even on maximal lipid-lowering therapy. Demonstrating that semaglutide provides additional LDL reduction positions it as a complementary agent for refractory hypercholesterolemia.

How the study worked

Single case report of oral semaglutide added to intensive lipid-lowering therapy.

What this study cannot tell us

Single case. Cannot quantify the additional LDL reduction precisely from abstract. Mechanism of semaglutide LDL lowering unclear.

How to read the evidence

Single case report. Important observation but cannot establish magnitude or generalizability.

When this study was published

Published in 2025.

The bigger picture

Semaglutide's LDL-lowering effect is unique among GLP-1 drugs and appears additive to PCSK9 inhibitors. This adds lipid management to semaglutide's growing cardiovascular benefit portfolio.

Questions still open

What mechanism drives semaglutide's LDL reduction?
Should semaglutide be considered for residual LDL risk?
Is the LDL effect specific to semaglutide or shared by all GLP-1 drugs?

Common questions

Can semaglutide lower cholesterol?

This case shows oral semaglutide reduced LDL cholesterol further even in a patient already on maximum lipid-lowering therapy (statin + ezetimibe + PCSK9 inhibitor). This additive LDL-lowering effect is unique to semaglutide among GLP-1 drugs and adds another cardiovascular benefit.

Why is this significant for familial hypercholesterolemia?

Patients with genetic high cholesterol often cannot reach target LDL even on maximum drug therapy. Finding that semaglutide provides additional LDL reduction on top of three lipid-lowering drugs suggests it could help close this treatment gap for high-risk patients.

Read the original research

Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.

Internal medicine (Tokyo, Japan)

View on PubMed ↗Publisher’s paper ↗

Citation

Tada, Hayato; Takamura, Masayuki. (2025). Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.. Internal medicine (Tokyo, Japan). https://doi.org/10.2169/internalmedicine.6198-25